- ISIN
- US00091F1066
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Oct 11, 2017
Highlights
- Market Cap
- $33.59M
- Enterprise Value
- $37.40M
- EPS (TTM)
- -$0.32
- Gross Profit (TTM)
- $581.91K
- EBITDA (TTM)
- -$6.94M
- Year Range
- $0.88 - $5.48
- ROA (TTM)
- -36.47%
- ROE (TTM)
- -66.80%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ABVC Performance Chart
ABVC Biopharma Inc (ABVC) is down 38.0% since the beginning of the year. At $1 per share, ABVC is trading 75.9% below its 52-week high of $5. Investors who bought $1,000 worth of ABVC shares 5 years ago would now be looking at an investment worth $26.
Loading charts...
Returns By Period
ABVC Biopharma Inc (ABVC) has returned -38.03% so far this year and -28.26% over the past 12 months.
ABVC Biopharma Inc
- 1D
- -2.22%
- 1M
- 15.79%
- YTD
- -38.03%
- 6M
- -43.83%
- 1Y
- -28.26%
- 3Y*
- -37.05%
- 5Y*
- -51.66%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
ABVC Monthly Returns History
Based on dividend-adjusted daily data since Oct 11, 2017, ABVC's average daily return is -0.01%, while the average monthly return is -2.83%.
Historically, 37% of months were positive and 63% were negative. The best month was Jun 2025 with a return of +62.4%, while the worst month was Jul 2023 at -52.1%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 6 months.
On a daily basis, ABVC closed higher 33% of trading days. The best single day was Nov 1, 2021 with a return of +137.4%, while the worst single day was Jul 8, 2019 at -50.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -5.16% | -35.15% | -25.95% | 6.17% | 36.89% | -6.38% | -38.03% | ||||||
| 2025 | -12.37% | 33.48% | 53.60% | -0.00% | 29.25% | 62.41% | 7.87% | 17.92% | 7.42% | -7.89% | -3.21% | -21.40% | 261.02% |
| 2024 | 31.03% | -20.39% | 8.26% | -4.58% | -36.47% | -2.53% | 0.67% | -13.33% | 1.20% | 1.11% | -23.30% | 11.32% | -49.14% |
| 2023 | 15.44% | -7.97% | -3.61% | 6.25% | 0.01% | -23.61% | -52.07% | -47.39% | -20.61% | 3.85% | 16.67% | -7.94% | -81.44% |
| 2022 | -26.25% | -0.80% | 10.08% | -12.45% | -17.15% | -46.46% | -38.68% | 55.38% | -12.87% | -17.05% | 1.19% | -15.39% | -81.56% |
| 2021 | -1.96% | -16.40% | 7.66% | 0.00% | 22.22% | -8.18% | -2.18% | -41.30% | -20.34% | 9.96% | 19.69% | 11.51% | -33.53% |
Benchmark Metrics
ABVC Biopharma Inc has an annualized alpha of -5.73%, beta of 0.18, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since October 11, 2017.
- This stock participated in 156.53% of S&P 500 Index downside but only -67.03% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.18 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -5.73%
- Beta
- 0.18
- R²
- 0.00
- Upside Capture
- -67.03%
- Downside Capture
- 156.53%
Return for Risk
Risk / Return Rank
ABVC ranks 34 for risk / return — below 34% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for ABVC Biopharma Inc (ABVC) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ABVC | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.31 | ||
| Sortino ratioReturn per unit of downside risk | -2.48 | ||
| Omega ratioGain probability vs. loss probability | 1.03 | 1.37 | -0.33 |
| Calmar ratioReturn relative to maximum drawdown | -0.35 | 2.78 | -3.14 |
| Martin ratioReturn relative to average drawdown | -0.51 | 12.44 | -12.95 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the ABVC Biopharma Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the ABVC Biopharma Inc was 99.89%, occurring on Feb 13, 2025. The portfolio has not yet recovered.
The current ABVC Biopharma Inc drawdown is 99.65%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -99.89%Feb 2025 | 6y 1mo | — | 7y 5moJan 2019 - now |
Rate-hike selloffLate 2018 | -25.00%Dec 2018 | 7mo 13d | 15d | 7mo 28dMay 2018 - Jan 2019 |
Drawdown Indicators
| ABVC | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.89% | -56.78% | -43.11% |
Max Drawdown (1Y)Largest decline over 1 year | -80.81% | -9.10% | -71.71% |
Max Drawdown (3Y)Largest decline over 3 years | -92.64% | -18.90% | -73.74% |
Max Drawdown (5Y)Largest decline over 5 years | -99.31% | -25.43% | -73.88% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -99.65% | -1.80% | -97.85% |
Average DrawdownAverage peak-to-trough decline | -78.80% | -10.71% | -68.09% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 55.47% | 2.03% | +53.44% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of ABVC Biopharma Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how ABVC Biopharma Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ABVC in comparison with other companies in the Biotechnology industry. Currently, ABVC has a P/B value of 3.1. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ABVC
Add ABVC Biopharma Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ABVC